Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension

Eye

Volumn 24, Issue 7, 2010, Pages 1234-1242

  Miglior, S ^a   Grunden, J W ^b   Kwok, K ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b PFIZER INC   (United States)

Author keywords

dorzolamide; fixed combination; latanoprost; ocular hypertension; open angle glaucoma; timolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; TIMOLOL;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY;

EID: 77954703386     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.307     Document Type: Article

References (41)

1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-497.
2. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.
3. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observermasked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999; 8: 24-30.
4. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000; 130: 832-833.
5. Holló G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006; 16: 816-823.
6. Hommer A, Kapik B, Shams N, The Unoprostone Adjunctive Therapy Study Group. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003; 87: 592-598.
7. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology 1996; 103: 1283-1293.
8. Wang RF, Serle JB, Gagliuso DJ, Podos SM. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. J Glaucoma 2000; 9: 458-462.
9. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102: 1743-1752.
10. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916-1924.
11. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a sixmonth masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138-147.
12. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703.
13. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103: 126-137.
14. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2a analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297-1304.
15. Weinreb RN, Toris CB, Gabelt BT, Lindey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47(Suppl 1): S53-S64.
16. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111: 1351-1358.
17. Alm A,Widengard I, Kjellgren D, SöderströmM, Friström B, Heijl A et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79: 12-16.
18. Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991; 98: 1079-1082.
19. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994; 78: 899-902.
20. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd edn. DOGMA, Srl: Savona, Italy, 2008.
21. Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83: 711-716.
22. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233-236.
23. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of oncedaily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533-540.
24. Tsai JC, McClure CA, Ramos SE, Schundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12: 393-398.
25. Latanoprost/Timolol Fixed Combination Investigators Brochure (Pfizer internal document, New York, NY). June 2004, p 100.
26. Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002; 133: 753-757.
27. Wayman L, Larsson LI, Maus T, Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115: 1368-1371. (Pubitemid 28055863)
28. Konstas AG, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999; 128: 15-20.
29. Konstas AGP, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol 2008; 92: 1498-1502.
30. Martinez A, Sanchez M. Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients.Int J Clin Prac 2007; 61: 815-825.
31. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111: 276-282.
32. Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/ timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 2004; 18: 1264-1269.
33. Garcia-Sanchez J, Rouland JF, Spiegel D, Pajic B, Cunliffe I, Traverso C et al. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol 2004; 88: 877-883.
34. Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs the concomitant brimonidine and latanoprost therapy. Eye 2004; 18: 990-995.
35. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006; 113: 70-76.
36. Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357-1360.
37. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453-457.
38. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42-48.
39. Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/ timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 2008; 115: 99-103.
40. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 2002; 134: 749-760.
41. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003; 48(Suppl 1): S17-S20.